Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Lori Leslie, MD, on real-world outcomes in CLL patients receiving ibrutinib or chemoimmunotherapy

Dr. Leslie, Director, Indolent Lymphoma and Chronic Leukemia Research Programs, John Theurer Cancer Center at Hackensack University Medical Center, discusses real-world outcomes among patients with chronic lymphocytic leukemia (CLL) receiving first-line ibrutinib versus chemoimmunotherapy presented at the 62nd Annual ASH Meeting & Exposition

Tags: ASH Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Published: 09 December 2020

Recent Videos

video

Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021

Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the ...

video

Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

video

Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial

Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial

video

Zev Wainberg, MD, discusses the safety profile of bemarituzumab

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

video

Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial

Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial

video

Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

video

Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial

Dr. George, Director, GI Oncology Program, University of Florida, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial ...

video

Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer

Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology ...

video

Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer

Dr. George, Director, GI Oncology Program, University of Florida, speculates on the evolving treatment landscape of locally advanced rectal cancer ...

video

Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021

Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, tells us ...

Related Videos

video-image

Zev Wainberg, MD, considers the influence of ctDNA testing in the treatment of gastric cancer

video-image

Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial

video-image

Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types

video-image

Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial

video-image

Zev Wainberg, MD, discusses the safety profile of bemarituzumab

video-image

Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial

video-image

Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021

video-image

Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021

video-image

Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer

video-image

Rachna Shroff, MD, considers the progress of targeted therapies in GI cancer

video-image

Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers

video-image

Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer

video-image

Rachna Shroff, MD, elaborates on newly approved targeted therapies in esophagogastric cancer

video-image

Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021

video-image

Kevin Kalinsky, MD, considers the practice-changing potential of RxPONDER

video-image

Kevin Kalinsky, MD, offers considerations when treating patients with HR+, HER2- breast cancer

video-image

Kevin Kalinsky, MD, regarding CTCs as a predictor of overall survival in metastatic breast cancer

video-image

Kevin Kalinsky, MD, shares thoughts on the DESTINY-Breast01 clinical trial from SABCS 2020

video-image

Kevin Kalinsky, MD, summarizes recent clinical data regarding the role of CDK 4/6 inhibitors

video-image

Kevin Kalinsky, MD, shares impressions of the RxPONDER clinical trial presented at SABCS 2020